Ignite Creation Date:
2025-12-24 @ 4:25 PM
Ignite Modification Date:
2025-12-28 @ 6:56 AM
Study NCT ID:
NCT04109066
Status:
COMPLETED
Last Update Posted:
2025-01-08
First Post:
2019-09-27
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-11-18
Start Date Type:
ACTUAL
Primary Completion Date:
2023-01-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-12-27
Completion Date Type:
ACTUAL
First Submit Date:
2019-09-27
First Submit QC Date:
None
Study First Post Date:
2019-09-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-01-12
Results First Submit QC Date:
None
Results First Post Date:
2024-03-12
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-12-16
Last Update Post Date:
2025-01-08
Last Update Post Date Type:
ACTUAL